Immunization with a Combination of Merozoite Surface Proteins 4/5 and 1 Enhances Protection against Lethal Challenge withPlasmodium yoelii
Open Access
- 1 December 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (12) , 6606-6613
Abstract
It is widely believed that subunit vaccines composed of multiple components will offer greater protection against challenge by malaria, and yet there is little experimental evidence to support this view. We set out to test this proposition in thePlasmodium yoeliichallenge system in rodents by comparing the degree of protection conferred by immunization with a mixture of merozoite surface proteins to that conferred by single proteins. We therefore examined a defined protein mixture made of the epidermal growth factor-like domains ofP. yoellimerozoite surface protein 1 (MSP1) and MSP4/5, the homologue ofP. falciparumMSP4 and MSP5. In the present study we demonstrate that this combination of recombinant proteins dramatically enhances protection against lethal malaria challenge compared to either protein administered alone. Many mice immunized with the MSP4/5 plus MSP119combination did not develop detectable parasitemia after challenge. Combined immunization with MSP119and yMSP4/5, a product characterized by lower protective efficacy, also greatly enhanced protection by reducing peak parasitemias and increasing the numbers of survivors. In some combination trials, levels of antibodies to MSP119were elevated compared to the MSP119alone group; however, improved protection occurred regardless of whether boosting of the anti-MSP119response was observed. Boosting of anti-MSP119did not appear to be due to contaminating endotoxin in the EcMSP4/5 material since enhanced protection was observed in C3H/HeJ mice, which are endotoxin insensitive. Collectively, these experiments show that multiantigen combinations offer enhanced levels of protection against asexual stage infection and suggest that combinations of MSP1, MSP4, and MSP5 should be evaluated further for use in humans.Keywords
This publication has 42 references indexed in Scilit:
- Immunization with RecombinantPlasmodium yoeliiMerozoite Surface Protein 4/5 Protects Mice against Lethal ChallengeInfection and Immunity, 2000
- Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteersVaccine, 2000
- Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)Journal of Experimental Medicine, 1999
- Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC‐Pf7, a Pox‐Vectored, Multiantigen, Multistage Vaccine Candidate forPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 1998
- An efficacy trial of the malaria vaccine SPf66 in Gambian infants—second year of follow-upVaccine, 1998
- Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.Journal of Experimental Medicine, 1995
- Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP119) variants secreted from Saccharomyces cerevisiaeMolecular and Biochemical Parasitology, 1994
- A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malariaNature, 1988
- Induction of protective immunity against experimental infection with malaria using synthetic peptidesNature, 1987
- Immunization against blood-stage rodent malaria using purified parasite antigensNature, 1981